oxford nanopore technologies
dgmacarthur | January 12, 2010The big news from the JP Morgan investment conference today is the announcement of a brand new shiny sequencing machine from Illumina, the HiSeq 2000. The new machine boasts an impressive set of statistics, and looks likely to gradually replace Illumina's GAIIx as the workhorse of most modern sequencing facilities.
So, how excited should we be?
Let's be clear about this up front: this new machine, while impressive, represents an incremental advance rather than a dramatic technological leap forward. This is still second-generation sequencing, generating relatively small snippets of DNA…
dgmacarthur | January 4, 2010
The Gene Sherpa predicts that Complete Genomics will win the Archon X Prize in Genomics in 2010. In the comments, Keith Robison is wisely skeptical. I agree with Keith - it's unlikely that the X Prize will be won this year, and if it is the winner is unlikely to be Complete Genomics.
For those who don't know the prize, here's the brief summary: the X Prize Foundation will give US$10 million to the first team to satisfy the following conditions:
sequence 100 human genomes within 10 days or less, with
an accuracy of no more than one error in every 100,000 bases sequenced [note that the…
dgmacarthur | October 6, 2009IBM's announcement that it will be entering the DNA sequencing technology race (which I mentioned briefly earlier today) has created a tremendous amount of mainstream media interest. That's understandable given IBM's size and history of innovation, but how likely are they to represent serious contenders for the potentially lucrative sequencing market?
Firstly, it's important to note that this announcement represents more of an expression of interest in the field rather than anything close to a mature technology; IBM will not be rolling out a machine to sequence your genome at any stage in…
dgmacarthur | October 6, 2009Things are as usual moving at ludicrous speed in the world of genomics, but sadly I only have time to post a few pointers to some of the most striking developments.
IBM is moving into the third-generation sequencing arena. The company is developing a new sequencing technology based on tiny nanopores - a field already being explored by the understated British nobility of sequencing, Oxford Nanopore. This is all over the news, but Dan Vorhaus has an introduction and is promising to follow up on further developments. You can also watch a pretty but largely content-free animation of the process…
dgmacarthur | September 16, 2009Kevin Davies from Bio-IT World has two interviews up today relevant to new DNA sequencing technologies.
Firstly, there's an excellent interview with Clive Brown, vice president of development and informatics for Oxford Nanopore Technologies - one of the most promising contenders in the rapidly evolving third-generation DNA sequencing market. Brown is renowned for his plain-speaking approach (in the article he's described as "the most honest guy in all of next-gen sequencing", a quote originating from David Dooling), and that shows here in his blunt comments on the recent Helicos genome…
dgmacarthur | August 26, 2009Complete Genomics is finally back on the road towards fulfilling its promises of $5000 human genome sequences, after delays in obtaining funding for a massive new facility pushed back its plans by six months. The $45 million in funding it announced this week will be sufficient to build the new Silicon Valley facility, which the company claims will have the capacity to sequence a staggering 10,000 genomes over the course of 2010.
Complete Genomics is an unusual creature in the second-generation sequencing menagerie: instead of aiming to generate revenue by selling machines to researchers and…
dgmacarthur | May 20, 2009BioArray News (subscription required) reports that genomic analysis technology provider Illumina has launched a new family of genotyping chips designed to simultaneously assay 4 million sites of variation in the human genome.
The chips are a major step up from the 1-million-feature chips that
currently represent the state of the art, and take advantage of several
public projects generating catalogues of human genetic variation (such
as the 1000 Genomes Project).
Illumina has also increased the density of markers in and around genes,
and fleshed out regions that have previously been…
dgmacarthur | February 23, 2009James Clarke, Hai-Chen Wu, Lakmal Jayasinghe, Alpesh Patel, Stuart Reid, Hagan Bayley (2009). Continuous base identification for single-molecule nanopore DNA sequencing Nature Nanotechnology DOI: 10.1038/nnano.2009.12
The clever boys and girls at Oxford Nanopore Technologies - one of the most quietly impressive contenders in the hotly-contested next-generation DNA sequencing race - have a new paper out in Nature Nanotechnology today. The paper demonstrates proof of principle for a crucial step in their approach to DNA sequencing, the accurate recognition of DNA bases as they pass through a…
dgmacarthur | January 12, 2009A press release today describes a potentially exciting partnership between two companies in the DNA sequencing space: Oxford Nanopore Technologies and Illumina.
Illumina is an established player in the field, providing one of the most widely-used second-generation sequencing platforms (the Genome Analyzer, previously known as Solexa). Oxford, in contrast, is a young but promising contestant in the increasingly heated race towards so-called "third-generation" sequencing technologies, which promise even more staggering increases in the ability of researchers to generate vast amounts of…